Entropy Neurodynamics (ASX:ENP) has reported Phase 2a clinical trial results showing that TRP-8802, an oral psilocybin therapy, rapidly and sustainably reduced binge eating episodes in patients with binge eating disorder.
Conducted at the University of Florida and published in the peer-reviewed Journal of Eating Disorders, the study found that all evaluable patients experienced significant reductions in binge-eating behaviour, maintained through a 14-week follow-up.
The trial of six patients, supported by structured therapy sessions, also demonstrated improvements in anxiety, depression, psychological flexibility, and waist circumference, with 80% of patients showing measurable abdominal reductions.
Neuroimaging suggested enhanced cognitive control and neural network reorganisation.
Professor Jessie Dallery, lead psychologist on the study, described the results as "clinically meaningful and highly promising," while ENP CEO Jason Carroll highlighted TRP-8803, the company's IV-infused psilocin candidate, as a next-generation therapy designed to offer a precision approach targeting both compulsive eating and underlying psychiatric drivers.
At the time of reporting, Entropy Neurodynamics' share price was $0.33.